CRISPR Therapeutics recently reported Phase 1b data for CTX310 in severe hypertriglyceridemia and early basket trial results for zugo cel in refractory autoimmune diseases, with both programs showing ...
Source LinkCRISPR Therapeutics recently reported Phase 1b data for CTX310 in severe hypertriglyceridemia and early basket trial results for zugo cel in refractory autoimmune diseases, with both programs showing ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.